Trial | NCT00219817  Report issue

Title

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    anamorelin ...

  • Study Participants

    80
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Study Started
Jun 30
2005
Primary Completion
Oct 31
2006
Study Completion
Oct 31
2006
Last Update
Sep 02
2013
Estimate

Drug RC-1291 HCl

Criteria 

Inclusion Criteria:

Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer.
Involuntary loss of body weight of ≥ 5 % within the past 6 months

Exclusion Criteria:

Presently hospitalized or in a nursing care facility.
Inability to increase food intake from secondary causes.
Liver disease
If female-pregnant, breast-feeding or of childbearing potential.
No Results Posted